Bank of New York Mellon Corp Sells 19,272,231 Shares of Kenvue Inc. $KVUE

Bank of New York Mellon Corp lessened its position in shares of Kenvue Inc. (NYSE:KVUE) by 63.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,088,034 shares of the company’s stock after selling 19,272,231 shares during the period. Bank of New York Mellon Corp owned approximately 0.58% of Kenvue worth $191,269,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Elyxium Wealth LLC bought a new position in Kenvue in the 4th quarter valued at approximately $26,000. Physician Wealth Advisors Inc. boosted its position in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares in the last quarter. Cornerstone Planning Group LLC grew its stake in shares of Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the last quarter. SBI Securities Co. Ltd. grew its stake in shares of Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares during the last quarter. Finally, Leonteq Securities AG acquired a new position in shares of Kenvue during the fourth quarter worth $45,000. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.59% of the company’s stock.

Kenvue Trading Up 4.9%

Shares of NYSE KVUE opened at $17.72 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $22.87. The firm has a 50 day moving average price of $17.37 and a two-hundred day moving average price of $17.48. The stock has a market cap of $34.01 billion, a P/E ratio of 20.84, a price-to-earnings-growth ratio of 1.28 and a beta of 0.54.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same period in the prior year, the company posted $0.24 EPS. The company’s revenue was up 4.5% on a year-over-year basis. As a group, equities analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on KVUE shares. Argus raised Kenvue to a “hold” rating in a report on Friday, March 6th. Weiss Ratings downgraded Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. UBS Group cut their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. Citigroup cut their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Finally, Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.